Docefrez Approval History
FDA Approved: Yes (First approved May 3, 2011)
Brand name: Docefrez
Generic name: docetaxel
Dosage form: for Injection
Company: Sun Pharmaceutical Industries Inc.
Treatment for: Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer
Marketing Status: Discontinued
Docefrez (docetaxel) is a microtubule inhibitor indicated for the treatment of metastatic breast cancer, metastatic non-small cell lung cancer and hormone refractory metastatic prostate cancer.
Development History and FDA Approval Process for Docefrez
|May 4, 2011||Sun Pharma Announces US FDA Approval for Docefrez (docetaxel) for Injection|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.